Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Shattuck Labs Inc (STTK)

Shattuck Labs Inc (STTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,769
  • Shares Outstanding, K 47,899
  • Annual Sales, $ 5,720 K
  • Annual Income, $ -75,410 K
  • EBIT $ -81 M
  • EBITDA $ -79 M
  • 60-Month Beta 1.63
  • Price/Sales 6.46
  • Price/Cash Flow N/A
  • Price/Book 0.55
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.49
  • Most Recent Earnings $-0.27 on 05/01/25
  • Next Earnings Date 08/07/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 509.00% ( +16.90%)
  • Historical Volatility 95.61%
  • IV Percentile 89%
  • IV Rank 57.07%
  • IV High 884.45% on 04/04/25
  • IV Low 9.84% on 08/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,137
  • Open Int (30-Day) 1,462

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.29
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +40.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7664 +6.99%
on 07/07/25
1.2350 -33.60%
on 06/10/25
-0.3700 (-31.09%)
since 06/09/25
3-Month
0.7314 +12.11%
on 04/17/25
1.2350 -33.60%
on 06/10/25
-0.1041 (-11.27%)
since 04/09/25
52-Week
0.6922 +18.46%
on 04/07/25
4.9900 -83.57%
on 07/16/24
-2.8900 (-77.90%)
since 07/09/24

Most Recent Stories

More News
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

STTK : 0.8196 (+1.26%)
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

STTK : 0.8196 (+1.26%)
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

STTK : 0.8196 (+1.26%)
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

STTK : 0.8196 (+1.26%)
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

STTK : 0.8196 (+1.26%)
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

STTK : 0.8196 (+1.26%)
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

STTK : 0.8196 (+1.26%)
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

STTK : 0.8196 (+1.26%)
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

STTK : 0.8196 (+1.26%)
Shattuck Labs, Inc. to Present at Piper Sandler and Evercore Investor Conferences in December 2024

Shattuck Labs will present at two investor conferences in December 2024, focusing on its novel cancer and autoimmune disease therapeutics.Quiver AI SummaryShattuck Labs, Inc., a biotechnology company focused...

STTK : 0.8196 (+1.26%)

Business Summary

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North...

See More

Key Turning Points

3rd Resistance Point 0.8878
2nd Resistance Point 0.8583
1st Resistance Point 0.8339
Last Price 0.8196
1st Support Level 0.7800
2nd Support Level 0.7505
3rd Support Level 0.7261

See More

52-Week High 4.9900
Fibonacci 61.8% 3.3482
Fibonacci 50% 2.8411
Fibonacci 38.2% 2.3340
Last Price 0.8196
52-Week Low 0.6922

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar